Optimal Regimen in Endovascular Therapy in Ischemic Cerebrovascular Disease Based on Clopidogrel Resistance

The Optimal Regimen of Medical Treatment in Endovascular Therapy in Ischemic Cerebrovascular Disease Based on Clopidogrel Resistance

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01925872

Acronym

ORETCR

Enrollment

2000

Registered

2013-08-20

Start date

2013-05-31

Completion date

2015-05-31

Last updated

2015-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic Cerebrovascular Disease

Keywords

ischemic cerebrovascular disease, Percutaneous transluminal angioplasty and stenting, Clopidogrel resistance

Brief summary

1. Clopidogrel resistance is common in patients of ischemic cerebrovascular disease. 2. Genetic polymorphisms are the most important factors to clopidogrel resistance. 3. The purpose of this study is to find the genes which are the related to clopidogrel resistance. 4. Through gene sequencing, we can filter patient of clopidogrel resistance, so another drug maybe used to avoid the undesired efficacy.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

25 Years to 95 Years

Healthy volunteers

Inclusion criteria

* symptomatic ischemic cerebrovascular disease caused by Intracranial atherosclerotic atherosclerosis research database. * 90 days had a stroke or transient ischemic attack is defined as symptomatic Intracranial atherosclerotic atherosclerosis * stenosis ≥ 50% (MRI or CT angiography). * Intracranial vascular stenosis measured according to the method reported Warfarin aspirin symptomatic intracranial disease research.

Exclusion criteria

* diffuse intracranial arterial stenosis. * cranial magnetic resonance imaging shows lesions as the branch artery blockage caused. * non-atherosclerotic lesions. * occurred within 6 weeks of vascular lesions in the region of intracranial hemorrhage. * potential cardiac thrombus source. * has concurrent intracranial tumors, intracranial aneurysm or arteriovenous malformation. * ipsilateral extracranial carotid or vertebral artery stenosis ≥ 50%; * known to heparin, aspirin, clopidogrel, anesthetics and contrast agents contraindications; * hemoglobin less than 10g/dL, platelet count \<100000/dL; * responsibility left after cerebral vascular-related serious neurological dysfunction (mRS ≥ 3); * international normalized ratio\> 1.5 * there are factors that can not be corrected by bleeding; * life expectancy \<1 year; * pregnant or lactating women; * indications Commission determines that the patient is not suitable for the study treatment.

Design outcomes

Primary

Measure	Time frame	Description
genotype, platelet aggregation rate, cerebrovascular events	2 years	Genotype means the genetic polymorphism of ABCB1, CES, CYP2C19, PON1, P2RY12, which can be determined through gene sequencing.

Secondary

Measure	Time frame	Description
Active metabolite concentration	2 years	Active metabolite concentration depend on the genetic polymorphism.

Outcome results